Cargando…
Aminoglycosides as potential inhibitors of SARS-CoV-2 main protease: an in silico drug repurposing study on FDA-approved antiviral and anti-infection agents
BACKGROUND: The emergence and spread of SARS-CoV-2 throughout the world has created an enormous socioeconomic impact. Although there are several promising drug candidates in clinical trials, none is available clinically. Thus, the drug repurposing approach may help to overcome the current pandemic....
Autores principales: | Ahmed, Mohammad Z., Zia, Qamar, Haque, Anzarul, Alqahtani, Ali S., Almarfadi, Omar M., Banawas, Saeed, Alqahtani, Mohammed S., Ameta, Keshav L., Haque, Shafiul |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Author(s). Published by Elsevier Ltd on behalf of King Saud Bin Abdulaziz University for Health Sciences.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7871101/ https://www.ncbi.nlm.nih.gov/pubmed/33866129 http://dx.doi.org/10.1016/j.jiph.2021.01.016 |
Ejemplares similares
-
Virtual screening and repurposing of FDA approved drugs against COVID-19 main protease
por: Kandeel, Mahmoud, et al.
Publicado: (2020) -
Repurposing FDA-approved drugs as FXR agonists: a structure based in silico pharmacological study
por: Jose, Sandra, et al.
Publicado: (2023) -
Repurposing of existing FDA approved drugs for Neprilysin inhibition: An in-silico study
por: Sankhe, Runali, et al.
Publicado: (2021) -
Repurposing of US-FDA approved drugs against SARS-CoV-2 main protease (M(pro)) by using STD-NMR spectroscopy, in silico studies and antiviral assays
por: Khan, Abdul Mateen, et al.
Publicado: (2023) -
In silico screening of FDA approved drugs reveals ergotamine and dihydroergotamine as potential coronavirus main protease enzyme inhibitors
por: Gurung, Arun Bahadur, et al.
Publicado: (2020)